When managing side effects from highly effective therapies like MEK inhibitors, it's often better to temporarily hold treatment and then resume at the original dose rather than immediately dose-reducing. This strategy maintains dose intensity, which is critical for maximizing the drug's therapeutic benefit.

Hyperglycemia, a common side effect of the PI3K inhibitor Inavolycib, is directly linked to better patient outcomes. Patients with more hyperglycemia showed a stronger response (hazard ratio 0.38 vs. 0.51). This reframes a negative side effect as a potential biomarker of efficacy, urging physicians to manage it rather than discontinue treatment.

While PARP inhibitors show some effect in all patients, clinical data revealed a significant survival advantage only in the HRD-positive subgroup. This has led to an FDA restriction, making biomarker testing a prerequisite for this class of drugs.

While trametinib carries a ~6% risk of congestive heart failure, this specific toxicity has not been observed with the avutametinib/defactinib combination. This distinct safety profile makes the doublet a potentially safer option, especially for patients with cardiac risk or who failed trametinib due to heart issues.

A patient who failed trametinib later responded to the avutametinib/defactinib combination. This suggests that resistance to one MEK inhibitor does not preclude a response to a different agent or combination targeting the same pathway, offering a viable later-line treatment strategy.

The risk of developing myeloid neoplasms from PARP inhibitors in the frontline ovarian cancer setting is very low, around 1%. However, it is critical to adhere to the recommended 2-3 year treatment duration and then stop the therapy to avoid unnecessary long-term risk.

A key clinical strategy for managing the TKI Zongertinib is proactive liver function monitoring. Checking AST/ALT every two weeks for the first three months allows clinicians to intervene with dose holds at the first sign of mild elevations, thereby preventing severe toxicity that would mandate a dose reduction.

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.

The perception that pills are less intense than infusions is a misconception. Patients on oral PARP inhibitors require constant monitoring for side effects like fatigue, nausea, and hematologic toxicities, especially in the first three months.